OncologyTube Professional - Patients Click Here
CancerGRACE - GRACEcasts
1,082,041 video views
CancerGRACE - GRACEcasts: Videos
03:00
How Rate of Progression Can Affect Treatment Decisions
by:cancergrace | 11 views
03:07
Dr. Benjamin Levy, Mount Sinai Health Systems, compares zoledronic acid and denosumab, two agents used for treatment of bone metastases in lung cancer.
by:cancergrace | 14 views
02:25
Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.
by:cancergrace | 15 views
04:34
Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.
by:cancergrace | 9 views
04:35
Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.
by:cancergrace | 17 views
02:55
Dr. Ross Camidge, University of Colorado, discusses the potential benefits as well as the disadvantages of multiplex mutation testing.
by:cancergrace | 11 views
01:46
Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.
by:cancergrace | 18 views
01:52
Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.
by:cancergrace | 16 views
00:55
Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.
by:cancergrace | 17 views
01:59
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.
by:cancergrace | 17 views
dsfsd